📗 Cite This Artifact
SLC39A1 — Solute Carrier Family 39 Member 1
SLC39A1 — Solute Carrier Family 39 Member 1 (ZIP1 Transporter)
Overview
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SLC39A1 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SLC39A1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Solute Carrier Family 39 Member 1</td></tr>
<tr><td><strong>Protein Name</strong></td><td>ZIP1 (Zrt-, Irt-like Protein 1)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>1q21.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[57191](https://www.ncbi.nlm.nih.gov/gene/57191)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607340](https://www.omim.org/entry/607340)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000143570</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y5L4](https://www.uniprot.org/uniprot/Q9Y5L4)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>477 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~54 kDa</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Cognitive Decline</td></tr>
</table>
</div>
SLC39A1 — Solute Carrier Family 39 Member 1 (ZIP1 Transporter)
Overview
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SLC39A1 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SLC39A1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Solute Carrier Family 39 Member 1</td></tr>
<tr><td><strong>Protein Name</strong></td><td>ZIP1 (Zrt-, Irt-like Protein 1)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>1q21.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[57191](https://www.ncbi.nlm.nih.gov/gene/57191)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607340](https://www.omim.org/entry/607340)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000143570</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9Y5L4](https://www.uniprot.org/uniprot/Q9Y5L4)</td></tr>
<tr><td><strong>Protein Size</strong></td><td>477 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~54 kDa</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Cognitive Decline</td></tr>
</table>
</div>
SLC39A1 encodes ZIP1 (Zrt-, Irt-like Protein 1), a critical zinc transporter that mediates zinc influx into cells. This protein is a member of the ZIP (Zrt-, Irt-like Protein) family of metal transporters, which play essential roles in maintaining cellular zinc homeostasis. In the central nervous system, ZIP1 is particularly important for neuronal zinc dynamics, synaptic function, and has been implicated in the pathogenesis of multiple neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@huang2005] [@liuzzi2004]
Zinc is the second most abundant trace metal in the brain after iron, serving as both a structural and signaling ion. Proper zinc homeostasis is essential for neuronal function, neurotransmitter release, synaptic plasticity, and long-term potentiation (LTP). Dysregulation of zinc homeostasis has emerged as a significant contributor to neurodegeneration, making zinc transporters like SLC39A1 important therapeutic targets. [@adlard2010] [@kim2014]
Gene Structure and Expression
Genomic Organization
The SLC39A1 gene is located on chromosome 1q21.3 and consists of 12 exons spanning approximately 14 kb of genomic DNA. The gene encodes a membrane protein with 8 predicted transmembrane domains. The promoter region contains response elements for various transcription factors including metal-responsive element-binding transcription factor 1 (MTF1), allowing for regulation by cellular zinc levels. [@liuzzi2004]
| Property | Value |
|----------|-------|
| Chromosome | 1q21.3 |
| Genomic Size | ~14 kb |
| Exon Count | 12 |
| Protein Length | 477 amino acids |
| Molecular Weight | ~54 kDa |
| Transcript Variants | 3 validated isoforms |
Tissue Distribution
SLC39A1 exhibits broad but tissue-specific expression:
- Brain: High expression in cortex, hippocampus, cerebellum, and basal ganglia
- Neurons: Enriched in excitatory neurons, particularly in dendritic compartments
- Astrocytes: Moderate expression in astrocytes
- Other tissues: Liver, kidney, pancreas, testis
Within the brain, ZIP1 is localized to both presynaptic terminals and postsynaptic dendritic spines, positioning it to regulate synaptic zinc levels during neurotransmission. The protein localizes to the plasma membrane and intracellular compartments, including the endoplasmic reticulum and Golgi apparatus. [@huang2005]
Cellular Localization
ZIP1 exhibits distinct subcellular localization patterns:
Protein Structure and Function
Domain Architecture
ZIP1 contains characteristic features of the ZIP family:
| Domain | Position | Function |
|--------|----------|----------|
| N-terminal extracellular domain | 1-70 aa | Zinc sensing, dimerization |
| Transmembrane domain 1 | 70-95 aa | Membrane anchoring |
| Variable loop | 95-130 aa | Extracellular loop between TM1-2 |
| Transmembrane domains 2-7 | 130-380 aa | Core transport domain |
| C-terminal cytosolic domain | 380-477 aa | Regulatory functions |
The transport mechanism involves a "rocker-switch" model where transmembrane helices pivot to allow zinc passage through a central pore. The protein can function as a homodimer or heterodimer with other ZIP family members. [@liuzzi2004]
Zinc Transport Mechanism
ZIP1 mediates zinc uptake through the following mechanism:
Unlike ZnT (zinc transporter) proteins that efflux zinc, ZIP transporters mediate zinc influx. This coordinated action between ZIP and ZnT proteins maintains cytosolic zinc within a narrow physiological range (typically 100-500 nM free zinc). [@kim2014]
Regulation of ZIP1 Expression
ZIP1 expression is regulated at multiple levels:
- Transcriptional regulation: MTF1-mediated upregulation under zinc deficiency
- Post-translational modification: Phosphorylation affects trafficking and activity
- Transcriptional repression: Under zinc sufficiency, ZIP1 expression decreases
- Epigenetic regulation: DNA methylation patterns affect long-term expression
Role in Neurodegeneration
Alzheimer's Disease
SLC39A1 has been extensively studied in Alzheimer's disease pathogenesis:
Expression Changes:
- ZIP1 is overexpressed in AD brain tissue, particularly in regions with high amyloid burden
- Increased expression correlates with amyloid-beta (Aβ) plaque density
- Upregulation may represent a compensatory response to cellular zinc dysregulation
- [@colvin2008]
Therapeutic Implications:
- ZIP1 inhibitors may reduce zinc-driven Aβ aggregation
- Modulating ZIP1 could restore synaptic zinc homeostasis
- Combination approaches targeting multiple zinc transporters show promise
The relationship between ZIP1 and tau pathology has been specifically investigated, with studies showing that ZIP1 expression correlates with tau burden in AD brains, suggesting a connection between zinc homeostasis and tau-driven neurodegeneration. [@davies2015]
Parkinson's Disease
In Parkinson's disease, ZIP1 contributes to pathogenesis through several mechanisms:
Motor Neuron Degeneration:
- ZIP1-mediated zinc influx is increased in PD dopaminergic neurons
- Zinc dysregulation promotes mitochondrial dysfunction
- Elevated intracellular zinc activates apoptotic pathways
- [@cheng2021]
- Zinc promotes α-synuclein aggregation
- ZIP1 upregulation may increase vulnerability to α-synuclein pathology
- Altered zinc homeostasis affects protein degradation pathways
- ZIP1 modulators could protect dopaminergic neurons
- Zinc chelation approaches have shown preclinical efficacy
- Targeting ZIP1 in combination with other interventions may be beneficial
Amyotrophic Lateral Sclerosis (ALS)
ZIP1 dysfunction has been implicated in ALS pathogenesis:
- Motor neurons exhibit altered zinc homeostasis
- Increased ZIP1 expression in ALS spinal cord
- Zinc dysregulation contributes to excitotoxicity
- Mitochondrial zinc accumulation promotes oxidative damage
- [@k研究会2022]
Other Neurological Disorders
ZIP1 has been implicated in several additional conditions:
Synaptic Function and Zinc Signaling
Synaptic Zinc Dynamics
Zinc serves as a neuromodulator in the brain, and ZIP1 plays a critical role:
ZIP1 in Synaptic Plasticity
ZIP1 contributes to synaptic plasticity through multiple mechanisms:
- LTP induction: Zinc influx through ZIP1 is necessary for memory formation
- LTD modulation: Zinc signaling regulates synaptic depression
- Dendritic spine morphology: ZIP1 affects spine density and shape
- Receptor trafficking: Zinc modulates AMPA and NMDA receptor distribution
- [@yang2018]
Zinc Signaling Pathways
Zinc modulates several key neuronal signaling pathways:
| Pathway | ZIP1's Role |
|--------|-------------|
| NMDA receptor signaling | Zinc is an endogenous modulator |
| mTOR signaling | Zinc regulates mTOR activity |
| MAPK/ERK pathway | Zinc affects downstream signaling |
| Ca²⁺ signaling | Zinc interacts with calcium pathways |
| 氧化应激反应 | Zinc is a cofactor for antioxidant enzymes |
Therapeutic Implications
ZIP1 as a Drug Target
Modulating ZIP1 activity represents a therapeutic strategy:
| Approach | Mechanism | Development Stage |
|----------|-----------|-------------------|
| ZIP1 inhibitors | Reduce zinc influx | Preclinical |
| ZIP1 agonists | Enhance zinc transport | Discovery |
| Zinc chelation | Reduce zinc availability | Clinical trials |
| Gene therapy | Modulate ZIP1 expression | Preclinical |
Alzheimer's Disease Therapy
Potential therapeutic applications in AD include:
Clinical trials with zinc chelators (e.g., clioquinol, PBT2) have shown some efficacy, validating zinc homeostasis as a therapeutic target. [@barnham2021]
Parkinson's Disease Therapy
ZIP1-targeting strategies for PD:
- Neuroprotection: Reducing zinc-mediated mitochondrial damage
- α-Synuclein modulation: Decreasing zinc-driven aggregation
- Dopaminergic neuron survival: Maintaining proper zinc homeostasis
Combination Approaches
Given the complexity of zinc homeostasis, combination approaches may be most effective:
- Multiple zinc transporter targets: ZIP1 + ZnT modulators
- Synergistic interventions: ZIP1 + Aβ/tau targeting
- Cell-type specific delivery: Targeting specific neuronal populations
Cellular Signaling and Interactions
Protein-Protein Interactions
ZIP1 interacts with several key proteins:
| Interactor | Function | Relevance |
|------------|----------|-----------|
| MTF1 | Transcription factor | Zinc-dependent regulation |
| ZnT proteins | Zinc efflux | Homeostatic coordination |
| Metallothioneins | Zinc buffering | Intracellular zinc storage |
| Clathrin | Endocytosis | Membrane trafficking |
| PSD-95 | Synaptic scaffold | Synaptic localization |
Signaling Pathway Integration
ZIP1 integrates with major neuronal signaling pathways:
Expression in Development and Aging
Neurodevelopment
ZIP1 plays important roles in brain development:
- Prenatal development: Essential for neuronal proliferation and differentiation
- Postnatal development: Critical for synaptogenesis and circuit formation
- Critical periods: Zinc homeostasis is essential for proper development
- [@oneill2013]
Aging and Cognitive Decline
Age-related changes in ZIP1 contribute to cognitive decline:
- Expression changes: Altered ZIP1 expression in aged brain
- Functional consequences: Dysregulated zinc homeostasis
- Cognitive impact: Contributes to age-related memory impairment
- [@fujimura2020]
The decline in zinc homeostasis with aging represents a modifiable risk factor for cognitive decline and neurodegenerative disease. Interventions targeting zinc balance may have beneficial effects in aging populations.
Animal Models
Knockout Studies
- ZIP1 knockout mice: Show zinc deficiency phenotypes
- Conditional knockouts: Tissue-specific deletion reveals organ-specific functions
- Phenotypes: Growth retardation, impaired neurodevelopment
Transgenic Models
- ZIP1 overexpression: Increased susceptibility to AD-like pathology
- Zinc-deficient models: Cognitive impairment phenotypes
- Disease models: Crossbreeding with AD/PD models
Therapeutic Testing
- ZIP1 inhibitors: Tested in AD mouse models
- Zinc supplementation: Effects on cognition in aged animals
- Gene therapy approaches: AAV-mediated ZIP1 modulation
Biomarker Potential
Diagnostic Applications
ZIP1 has potential as a disease biomarker:
- Brain imaging: PET ligands targeting zinc dynamics
- CSF biomarkers: Zinc and ZIP1 levels in cerebrospinal fluid
- Blood markers: Peripheral ZIP1 expression as surrogate
Disease Monitoring
- Progression tracking: ZIP1 expression correlates with disease stage
- Treatment response: Changes in ZIP1 with therapy
- Prognostic value: ZIP1 as a prognostic indicator
Evolutionary Conservation
ZIP1 is highly conserved across species:
- Humans: Full-length functional protein
- Mice: 94% homology, functional conservation
- Zebrafish: Essential for development
- Drosophila: Ortholog with preserved function
Clinical Implications
Biomarkers and Diagnostics
ZIP1 expression and activity have potential clinical applications:
| Application | Method | Utility |
|-------------|-------|--------|
| Diagnostic biomarker | Blood/CSF ZIP1 levels | Disease progression tracking |
| Therapeutic target | ZIP1 modulators | Disease modification |
| Pharmacodynamic marker | Zinc flux measurements | Treatment response |
| Risk stratification | Genetic variants | Susceptibility assessment |
Ongoing Clinical Trials
Several approaches targeting zinc homeostasis are in development:
Patient Stratification
ZIP1-based patient stratification could identify those most likely to benefit from zinc-modulating therapies:
- ZIP1 overexpression: May indicate zinc dysregulation as disease driver
- ZIP1 loss-of-function variants: May benefit from zinc supplementation
- Expression correlation with biomarkers: Aβ burden, tau levels, clinical severity
Research Gaps and Future Directions
Unresolved Questions
Despite significant progress, several key questions remain:
Emerging Research Areas
Emerging areas of investigation include:
- Single-cell analysis: Understanding ZIP1 in specific neuronal populations
- Spatial transcriptomics: Mapping ZIP1 expression in disease brains
- Structural biology: Cryo-EM studies of ZIP1 transport mechanism
- Aging studies: ZIP1 changes in normal aging vs. neurodegeneration
Animal Models
Knockout Studies
- ZIP1 knockout mice: Show zinc deficiency phenotypes including growth retardation, impaired neurodevelopment, and cognitive deficits
- Conditional knockouts: Tissue-specific deletion reveals organ-specific functions
- Phenotypes: Altered synaptic plasticity, impaired LTP, memory deficits
Transgenic Models
- ZIP1 overexpression: Increased susceptibility to AD-like pathology in mouse models
- Zinc-deficient models: Cognitive impairment phenotypes that mirror aging
- Disease models: Crossbreeding with APP/PS1 or α-synuclein transgenic mice
Therapeutic Testing
- ZIP1 inhibitors: Tested in AD mouse models with some success in reducing plaque burden
- Zinc supplementation: Mixed results in aged animals - some cognitive improvement, others show adverse effects
- Gene therapy approaches: AAV-mediated ZIP1 modulation showing promise in preclinical studies
Summary
SLC39A1 encodes ZIP1, a critical zinc transporter essential for neuronal zinc homeostasis. Through its role in zinc uptake, ZIP1 modulates synaptic function, neurotransmitter signaling, and neuronal survival. Dysregulation of ZIP1 has been implicated in multiple neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease, and ALS. The protein represents a promising therapeutic target, with modulation of ZIP1 activity offering potential for disease modification in these conditions. Understanding the precise mechanisms of ZIP1 dysfunction in neurodegeneration will be essential for developing effective therapeutic interventions.
See Also
- [Zinc Transporters](/mechanisms/zinc-transporters)
- [Zinc Homeostasis in Neurodegeneration](/mechanisms/zinc-homeostasis-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Synaptic Zinc Signaling](/mechanisms/synaptic-zinc)
- [ZIP Family Proteins](/proteins/zip-family)
- [Metallothioneins](/proteins/metallothioneins)
External Links
- [NCBI Gene: SLC39A1](https://www.ncbi.nlm.nih.gov/gene/57191)
- [UniProt: Q9Y5L4](https://www.uniprot.org/uniprot/Q9Y5L4)
- [Ensembl: ENSG00000143570](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000143570)
- [OMIM: 607340](https://www.omim.org/entry/607340)
Brain Atlas Resources
- [Allen Human Brain Atlas - SLC39A1](https://human.brain-map.org/microarray/search/show?search_term=SLC39A1): Gene expression data from adult human brain
- [BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/search?gene=SLC39A1): Developmental expression patterns
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/search?query=SLC39A1): Mouse brain expression data
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/?#): Cell type-specific expression data
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-slc39a1 |
| kg_node_id | SLC39A1 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-b8318b19b298 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-slc39a1'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-slc39a1?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[SLC39A1 — Solute Carrier Family 39 Member 1](http://scidex.ai/artifact/wiki-genes-slc39a1)
http://scidex.ai/artifact/wiki-genes-slc39a1